Alzheimer's & Dementia
Journal Information
ISSN / EISSN :
1552-5260 / 1552-5279
Current Publisher: Wiley (10.1002)
Former Publisher:
Elsevier BV (10.1016)
, Wiley (10.1016)
Total articles ≅ 38,590
Current Coverage
SCOPUS
PUBMED
MEDLINE
MEDICUS
SCIE
Archived in
SHERPA/ROMEO
Filter:
Latest articles in this journal
Alzheimer's & Dementia; doi:10.1002/alz.12223
The publisher has not yet granted permission to display this abstract.
Alzheimer's & Dementia; doi:10.1002/alz.12254
Abstract:
Intron retention (IR) has been implicated in the pathogenesis of complex diseases such as cancers; its association with Alzheimer's disease (AD) remains unexplored. We performed genome‐wide analysis of IR through integrating genetic, transcriptomic, and proteomic data of AD subjects and mouse models from the Accelerating Medicines Partnership‐Alzheimer's Disease project. We identified 4535 and 4086 IR events in 2173 human and 1736 mouse genes, respectively. Quantitation of IR enabled the identification of differentially expressed genes that conventional exon‐level approaches did not reveal. There were significant correlations of intron expression within innate immune genes, like HMBOX1, with AD in humans. Peptides with a high probability of translation from intron‐retained mRNAs were identified using mass spectrometry. Further, we established AD‐specific intron expression Quantitative Trait Loci, and identified splicing‐related genes that may regulate IR. Our analysis provides a novel resource for the search for new AD biomarkers and pathological mechanisms.
Alzheimer's & Dementia; doi:10.1002/alz.12216
The publisher has not yet granted permission to display this abstract.
Alzheimer's & Dementia; doi:10.1002/alz.12259
The publisher has not yet granted permission to display this abstract.
Alzheimer's & Dementia; doi:10.1002/alz.12262
Abstract:
Introduction This review aims to systematically identify and appraise the methodological quality of claims on the cost of delirium; and discuss challenges and opportunities for improvements in the precision of the estimates. Methods Searches of scientific papers and gray literature were performed up until June 2020. The Larg and Moss checklist was used to assess the methodological quality of the included studies. Results After deduplication, the search identified 317 potentially relevant articles, of which 17 articles were eligible for inclusion. After adjusting for inflation and common currency, the cost of delirium ranged between $806 and $24,509 (in 2019 US$). Discussion This review found significant variation among the cost estimates and methodological quality. There has been limited focus on dementia as a sequela of delirium in terms of economic implications, but recent evidence suggests cost implications of delirium may be 52% higher when dementia is considered.
Alzheimer's & Dementia; doi:10.1002/alz.12215
The publisher has not yet granted permission to display this abstract.
Alzheimer's & Dementia; doi:10.1002/alz.12238
The publisher has not yet granted permission to display this abstract.
Alzheimer's & Dementia; doi:10.1002/alz.12225
The publisher has not yet granted permission to display this abstract.
Alzheimer's & Dementia; doi:10.1002/alz.12277
The publisher has not yet granted permission to display this abstract.
Alzheimer's & Dementia; doi:10.1002/alz.12276
The publisher has not yet granted permission to display this abstract.